PARP1 and hepatocellular carcinoma: In a xenograft mouse model, PARP1 expression was reactivated in residual HCC tumors following treatment with Sorafenib [66], which implies that PARP1 could have a substantial impact on stem cell potency and the development of resistance to Sorafenib in HCC.